SICOR Announces ANDA Approval for Thiotepa for Injection

Apr 23, 2001, 01:00 ET from SICOR Inc.

    IRVINE, Calif., April 23 /PRNewswire Interactive News Release/ -- SICOR
 Inc. (Nasdaq: SCRI) today announced that its wholly owned subsidiary, Gensia
 Sicor Pharmaceuticals, Inc., has received approval of an Abbreviated New Drug
 Application (ANDA) from the Food and Drug Administration (FDA) for Thiotepa
 for Injection, a drug indicated for the treatment of carcinoma of the breast
 and ovaries, superficial papillary carcinoma of the urinary bladder, as well
 as various lymphomas such as Hodgkin's Disease.
     According to IMS, a market research firm, U.S. sales of thiotepa were
 approximately $19 million in 2000.  The branded product, Thioplex(R), is
 marketed by Immunex Corporation.
     SICOR Inc. is a vertically integrated specialty pharmaceutical company
 with proven expertise in the development, manufacturing and marketing of
 multi-source injectable pharmaceuticals.  With a strategy of combining both
 the production of active pharmaceutical ingredients utilizing chemical
 synthesis or fermentation and state of the art manufacturing facilities,
 SICOR's primary focus is on the worldwide injectable pharmaceutical market,
 which currently includes oncology, anesthesiology, cardiology and other
 therapeutic areas.  SICOR operates several manufacturing facilities in Europe,
 Mexico and the U.S.A., while maintaining the corporate headquarters in Irvine,
 California.
 
     This press release contains forward looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward looking statements and those matters set
 forth in the risk factors section of SICOR's filings on Forms 10-K and 10-Q
 with the Securities and Exchange Commission.  These forward looking statements
 represent the Company's judgment as of the date of this press release.  The
 Company disclaims any intent or obligation to update these forward looking
 statements.
 
     For more information on the Company, visit SICOR's web site at
 www.sicorinc.com.  News releases are also available at no charge through
 PR Newswire's News On-Call fax service.  For a menu of available news releases
 or to retrieve a specific release made by SICOR, call 800-758-5804, extension
 354050.  Please retain these numbers for future reference.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X55189677
 
 

SOURCE SICOR Inc.
    IRVINE, Calif., April 23 /PRNewswire Interactive News Release/ -- SICOR
 Inc. (Nasdaq: SCRI) today announced that its wholly owned subsidiary, Gensia
 Sicor Pharmaceuticals, Inc., has received approval of an Abbreviated New Drug
 Application (ANDA) from the Food and Drug Administration (FDA) for Thiotepa
 for Injection, a drug indicated for the treatment of carcinoma of the breast
 and ovaries, superficial papillary carcinoma of the urinary bladder, as well
 as various lymphomas such as Hodgkin's Disease.
     According to IMS, a market research firm, U.S. sales of thiotepa were
 approximately $19 million in 2000.  The branded product, Thioplex(R), is
 marketed by Immunex Corporation.
     SICOR Inc. is a vertically integrated specialty pharmaceutical company
 with proven expertise in the development, manufacturing and marketing of
 multi-source injectable pharmaceuticals.  With a strategy of combining both
 the production of active pharmaceutical ingredients utilizing chemical
 synthesis or fermentation and state of the art manufacturing facilities,
 SICOR's primary focus is on the worldwide injectable pharmaceutical market,
 which currently includes oncology, anesthesiology, cardiology and other
 therapeutic areas.  SICOR operates several manufacturing facilities in Europe,
 Mexico and the U.S.A., while maintaining the corporate headquarters in Irvine,
 California.
 
     This press release contains forward looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward looking statements and those matters set
 forth in the risk factors section of SICOR's filings on Forms 10-K and 10-Q
 with the Securities and Exchange Commission.  These forward looking statements
 represent the Company's judgment as of the date of this press release.  The
 Company disclaims any intent or obligation to update these forward looking
 statements.
 
     For more information on the Company, visit SICOR's web site at
 www.sicorinc.com.  News releases are also available at no charge through
 PR Newswire's News On-Call fax service.  For a menu of available news releases
 or to retrieve a specific release made by SICOR, call 800-758-5804, extension
 354050.  Please retain these numbers for future reference.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X55189677
 
 SOURCE  SICOR Inc.

RELATED LINKS

http://www.gensia.com/investrel.html